| Literature DB >> 19279650 |
A Hewagama1, D Patel, S Yarlagadda, F M Strickland, B C Richardson.
Abstract
Women develop chronic inflammatory autoimmune diseases more often than men. The mechanisms causing the increased susceptibility are incompletely understood. Chronic immune stimulation characterizes many autoimmune disorders. We hypothesized that repeated stimulation may cause a different T-cell response in women than in men. Microarrays were used to compare gene expression in T cells from healthy men and women with and without repeated stimulation. Four days after a single stimulation, only 25% of differentially expressed, gender-biased genes were expressed at higher levels in women. In contrast, after restimulation, 72% were more highly expressed in women. Immune response genes were significantly over-represented among the genes upregulated in women and among the immune response genes, the inflammatory/cytotoxic effector genes interferon-gamma (IFN-gamma), lymphotoxin beta (LTbeta), granzyme A (GZMA), interleukin-12 receptor beta2 (IL12Rbeta2), and granulysin (GNLY) were among those overexpressed to the highest degree. In contrast, IL17A was the only effector gene more highly expressed in men. Estrogen response elements were identified in the promoters of half the overexpressed immune genes in women, and in <10% of the male-biased genes. The differential expression of inflammatory/cytotoxic effector molecules in restimulated female T cells may contribute to the differences in autoimmune diseases between women and men.Entities:
Mesh:
Year: 2009 PMID: 19279650 PMCID: PMC2735332 DOI: 10.1038/gene.2009.12
Source DB: PubMed Journal: Genes Immun ISSN: 1466-4879 Impact factor: 2.676
FIGURE 1Expression profile of T cell genes differentially expressed between men and women
Bars shown greater than zero represent the numbers of genes expressed at higher levels in women than men, while the negative values represent the numbers of genes expressed more highly in men. Error bars represent the FDR of 4%.
Major GO-rankings for genes differentially expressed between women and men
| Term | GoID | Unrestimulated | Stimulated | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Female | Male Higher | Female | Male Higher | ||||||
| No of | Z | No of | Z | No of | Z | No of | Z | ||
| biological_process | GO:0008150 | 55 | 2.71 | 40 | 2.26 | 150 | 5.5 | 99 | 3.21 |
| cellular metabolic process | GO:0044237 | 35 | 2.85 | 17 | −0.17 | 78 | 2.28 | 56 | 1.49 |
| signal transduction | GO:0007165 | 18 | 2.16 | 10 | 0.64 | 53 | 4.59 | 31 | 2.41 |
| cell communication | GO:0007154 | 21 | 2.65 | 10 | 0.29 | 36 | 2.97 | 60 | 4.4 |
| transcription | GO:0006350 | 6 | −0.71 | 7 | 0.56 | 30 | 2.15 | 15 | 0.15 |
| regulation of gene expression | GO:0010468 | 6 | −0.83 | 7 | 0.44 | 28 | 1.45 | 17 | 0.53 |
| cell differentiation | GO:0030154 | 17 | 4.46 | 7 | 1.16 | 25 | 2.11 | 19 | 2.26 |
| intracellular signaling cascade | GO:0007242 | 9 | 1.87 | 22 | 3.35 | 15 | 2 | ||
| cell surface receptor linked signal transduction | GO:0007166 | 6 | 0.48 | 4 | 0.2 | 19 | 1.67 | 14 | 1.67 |
| cell death | GO:0008219 | 11 | 4.68 | 5 | 1.91 | 15 | 2.52 | 14 | 3.65 |
| apoptosis | GO:0006915 | 10 | 4.34 | 4 | 1.36 | 13 | 2.04 | 12 | 3.03 |
Gene sets with fold change ≥1.4 were analyzed using Genomatix BiblioSphere software to identify overrepresented GO groups.
GO analysis of immune genes
| Term | GoID | Female | Male Higher | ||
|---|---|---|---|---|---|
| No of | Z | No of | Z | ||
| immune system process | GO:0002376 | 21 | 4.70 | 15 | 4.09 |
| immune response | GO:0006955 | 20 | 5.68 | 11 | 3.79 |
| response to external stimulus | GO:0009605 | 18 | 4.90 | 10 | 2.84 |
| defense response | GO:0006952 | 14 | 3.84 | 10 | 3.34 |
| regulation of immune system process | GO:0002682 | 5 | 2.71 | 4 | 2.76 |
| immune system development | GO:0002520 | 4 | 1.58 | 4 | 2.40 |
| innate immune response | GO:0045087 | 4 | 2.83 | - | - |
Female-biased immune genes with fold change ≥1.4
| Gene Symbol | Gene | Locus | Gene Name | Fold | EREF |
|---|---|---|---|---|---|
| IFNG | 3458 | 12q14 | interferon, gamma | 1.8 | N |
| GZMA | 3001 | 5q11 | granzyme A(cytotoxic T-lymphocyte-associated serine esterase 3) | 1.7 | N |
| IL12RB2 | 3595 | 1p31 | interleukin 12 receptor, beta 2 | 1.7 | N |
| GNLY | 10578 | 2p11 | granulysin | 1.7 | Y |
| IL1F5 | 26525 | 2q14 | interleukin 1 family, member 5 (delta) | 1.5 | Y |
| CX3CL1 | 6376 | 16q13 | chemokine (C-X3-C motif) ligand 1 | 1.5 | N |
| MIST | 116449 | 4p16 | mast cell immunoreceptor signal transducer | 1.5 | N |
| LTB | 4050 | 6p21 | lymphotoxin beta (TNF superfamily, member 3) | 1.4 | Y |
| TRAT1 | 50852 | 3q13 | T cell receptor associated transmembrane adaptor 1 | 1.4 | N |
| CXCL2 | 2920 | 4q21 | chemokine (C-X-C motif) ligand 2 | 1.4 | N |
| IL16 | 3603 | 15q26 | interleukin 16 (lymphocyte chemoattractant factor) | 1.4 | Y |
| IFITM2 | 10581 | 11p15 | interferon induced transmembrane protein 2 (1–8D) | 1.4 | N |
| TLR10 | 81793 | 4p14 | toll-like receptor 10 | 1.4 | Y |
| DDX58 | 23586 | 9p12 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 | 1.4 | Y |
| SPINK5 | 11005 | 5q32 | serine peptidase inhibitor, Kazal type 5 | 1.4 | Y |
| OAS3 | 4940 | 12q24 | 2'-5'-oligoadenylate synthetase 3, 100kDa | 1.4 | Y |
| OAS1 | 4938 | 12q24 | 2',5'-oligoadenylate synthetase 1, 40/46kDa | 1.4 | Y |
| IFI6 | 2537 | 1p35 | interferon, alpha-inducible protein 6 | 1.4 | N |
| TNFRSF11A | 8792 | 18q22 | tumor necrosis factor receptor superfamily, member 11a, | 1.4 | N |
| MBP | 4155 | 18q23 | myelin basic protein | 1.4 | Y |
Male-biased immune genes with fold change ≥1.4
| Gene Symbol | Gene | Locus | Gene Name | Fold | EREF |
|---|---|---|---|---|---|
| AIM2 | 9447 | 1q22 | absent in melanoma 2 | −1.4 | N |
| FYN | 2534 | 6q21 | FYN oncogene related to SRC, FGR, YES | −1.4 | Y |
| IRF8 | 3394 | 16q24 | interferon regulatory factor 8 | −1.4 | N |
| SWAP70 | 23075 | 11p15 | SWAP-70 protein | −1.4 | N |
| IL17A | 3605 | 6p12 | interleukin 17A | −1.4 | N |
| IL10 | 3586 | 1q31 | interleukin 10 | −1.5 | N |
| IL5 | 3567 | 5q31 | interleukin 5 (colony-stimulating factor, eosinophil) | −1.5 | N |
| XCL1 | 6375 | 1q23 | chemokine (C motif) ligand 1 | −1.7 | N |
| CXCL10 | 3627 | 4q21 | chemokine (C-X-C motif) ligand 10 | −1.7 | N |
| CXCL9 | 4283 | 4q21 | chemokine (C-X-C motif) ligand 9 | −1.8 | N |
| HLA-DQA1 | 3117 | 6p21 | major histocompatibility complex, class II, DQ alpha 1 | −2 | N |
FIGURE 2Expression levels of pro-inflammatory transcripts in restimulated T cells from men and women
PBMC from 10 racially matched male-female pairs were stimulated with PHA, cultured 4 days, then restimulated for 6 hours with PMA + ionomycin. CD4+ and CD8+ T cells were isolated and expression levels of (A) LTB, (B) IFNG, (C) IL12RB2, (D) GZMA, (E) GNLY and (F) IL17A were measured by qRT- PCR relative to β-actin. Results are presented as the mean±SEM of the 10 determinations per group. Dark bars represent transcript levels in the women, and light bars transcript levels in the men.
FIGURE 3LTB, IL12RB2 and IFN-γ protein levels in restimulated T cells from men and women
(A) LTB and (B) IL12RB2 were measured by immunoblotting in the same restimulated CD4+ and CD8+ cells shown in figure 2. Results again are presented as the mean±SEM of the 10 determinations per group. (C) IFN-γ release by similarly restimulated T cells from 4 additional racially matched male-female pairs was measured by ELISA on the days indicated. Results again represent the mean±SEM of the 4 determinations per group.
Gene specific primer sequences
| Primer | Sequence |
|---|---|
| ACTB | f- GGA CTT CGA GCA AGA GAT GG |
| r- AGC ACT GTG TTG GCG TAC AG | |
| GZMA | f- ATTCTGGAAGCCCTTTGTTGTGCG |
| r- AGAATATAGACACCAGGCCCACGA | |
| IFNG | f- TGAACTGTCGCCAGCAGCTAAA |
| r- AGGCAGGACAACCATTACTGGGAT | |
| LTB | f- ATTACCTCTACTGTCTCGTCGGCT |
| r- TCCAGCACTGGAGTCACCGTCT | |
| GNLY | f- AAACACAGGAGCTGGGCCGTGACTA |
| r- GGTCGCAGCATTGGAAACACTTCT | |
| IL12RB2 | f- CTGTGAACGCTGAGCACACGATTT |
| r- TGCTGTGTCGCCTTGAGCAAGATA | |
| IL17A | f- AATCTCCACCGCAATGAGGA |
| r- ACGTTCCCATCAGCGTTGA |